Siberian Federal Biomedical Research Center

AO Angioline will invest over 500 million rubles (approx. $7.8 million) to build a plant in Novosibirsk, Russia, producing aortic valves, venous cava filters, occluders and vascular implants. The project is in partnership with the Meshalkin Research Center and is expected to launch in 2020.